| Previous Close | 4.9200 |
| Open | 4.9400 |
| Bid | 4.7700 x 1200 |
| Ask | 5.2200 x 1400 |
| Day's Range | 4.9300 - 5.0500 |
| 52 Week Range | 4.8600 - 9.2000 |
| Volume | 137,063 |
| Avg. Volume | 207,973 |
| Market Cap | 240.148M |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
RedHill is on track to launch Talicia® in the U.S. in the first quarter of 2020 for the treatment of H. pylori infection in adults- - - RedHill to sponsor H. pylori medical.
RedHill provided a notice of termination to Entera Health regarding the license agreement for EnteraGam® and the co-promotion agreement with Advanz Pharma Corp. for Donnatal® will not be renewed. RedHill has been promoting Donnatal® and EnteraGam® since mid-2017. “Prioritizing our commercial efforts allows us to focus on our most valuable products, Talicia® and Aemcolo®, as well as giving us capacity to bring on other important products, which are currently under discussion,” said Dror Ben-Asher, RedHill’s Chief Executive Officer.
“We are pleased to regain the rights to RHB-106, which aligns well with our expanded gastrointestinal-focused commercial activities in the U.S., and to pursue its development toward potential U.S. FDA approval,” said Dror Ben-Asher, RedHill’s CEO.
Aemcolo® (rifamycin) is a non-systemic antibiotic delivered directly to the site of non-invasive E. coli infection in the lower intestineAemcolo® is approved by the FDA for the.
Key Highlights: U.S. FDA approval of Talicia® for the treatment of Helicobacter pylori infection in adults Strategic partnership with Cosmo Pharmaceuticals, including.
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 15, 2019 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty.
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 13, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, today announced that it will report its third quarter 2019 financial results and operational highlights on Tuesday, November 19, 2019. The Company will host a conference call on Tuesday, November 19, 2019 at 8:30 a.m. EST to review the financial results and operational highlights. The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, http://ir.redhillbio.com/events.
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, today announced the publication of results from the Company’s Phase 3 study with RHB-102 (Bekinda®)1 in acute gastroenteritis (the GUARD study) in the Journal of the American Medical Association (JAMA) Network Open.
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 04, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Talicia® (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg1/250 mg/12.5 mg for the treatment of Helicobacter pylori (H. pylori) infection in adults. RedHill expects to launch Talicia in the U.S. in the first quarter of 2020 with its dedicated sales force.
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 29, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced that Mr. Adi Frish, Senior Vice President of Business Development and Licensing, will present a corporate overview at the BIO-Europe 2019 conference on Tuesday, November 12, 2019, at 2:30 p.m. CET, at the Hamburg Messe, Germany. A copy of Mr. Frish’s presentation will be available on the Company's website and may be viewed at: http://ir.redhillbio.com. RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company, primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases.
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 28, 2019 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty.
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 18, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced that it has entered into a strategic collaboration with Cosmo Pharmaceuticals N.V. (SIX:COPN) (“Cosmo”). The strategic collaboration includes an exclusive license agreement for the U.S. rights to Aemcolo® (rifamycin) and a simultaneous private investment by Cosmo of $36.3 million in RedHill at $7.00 per American Depositary Share (ADS), representing approximately 13.5% over the closing price on October 17, 2019, with a 180-day transfer restriction.
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 16, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced its support of a number of prevention and awareness initiatives for Stomach Cancer Awareness Month, including its sponsorship of the No Stomach For Cancer’s (NSFC) Spotlight on Stomach Cancer Symposium. The symposium will take place on Saturday, October 26, 2019, from 8 a.m. - 2 p.m. MST at the University of Arizona in Tucson, Arizona.
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 11, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced full Week 52 results for all subjects in the previously announced positive Phase 3 randomized, controlled study of RHB-104 in Crohn’s disease (the “MAP US study”) and supportive top-line results from the open-label extension Phase 3 study (the “MAP US2 study”). The full Week 52 results of blinded treatment in the MAP US Phase 3 study with RHB-104 were consistent with the previously reported positive outcomes of the study.
TEL-AVIV, Israel and RALEIGH, N.C., Sept. 26, 2019 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty.
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 27, 2019 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty.
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced that it will present data from the positive Phase 3 clinical studies of RHB-105 (Talicia®)1 for H. pylori infection and RHB-104 for Crohn’s disease at the upcoming American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting (October 25-30, 2019). In addition, an oral presentation on RHB-105 (Talicia) was also accepted for presentation at the XXXIInd International Workshop on Helicobacter & Microbiota in Inflammation and Cancer of the European Helicobacter and Microbiota Study Group (EHMSG 2019) (September 5-7, 2019).
Key Highlights and Upcoming Milestones: U.S. FDA acceptance of the New Drug Application (NDA) for Talicia® for H. pylori for priority review and assignment of a target PDUFA.
NEW YORK, NY / ACCESSWIRE / July 23, 2019 / RedHill Biopharma Ltd. (NASDAQ: RDHL ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 23, 2019 at 8:30 AM ...
TEL-AVIV, Israel and RALEIGH, N.C., July 15, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced that it will report its second quarter 2019 financial results and operational highlights on Tuesday, July 23, 2019. The Company will host a conference call on Tuesday, July 23, 2019 at 8:30 a.m. EDT to review the second quarter 2019 financial results and operational highlights. The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, http://ir.redhillbio.com/events.
TEL-AVIV, Israel and RALEIGH, N.C., July 03, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Talicia® (RHB-105)1 for H. pylori infection. The NDA for Talicia has also been granted Priority Review designation and was assigned a target Prescription Drug User Act (PDUFA) action date by the FDA of November 2, 2019.
TEL-AVIV, Israel and RALEIGH, N.C., June 10, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a new patent covering RHB-104 for Crohn’s disease and RHB-204 for Mycobacterium avium complex (MAC) disease, the most common cause of pulmonary nontuberculous mycobacteria (NTM) infections1. Once granted, the patent is expected to be valid until at least 2029.
TEL-AVIV, Israel and RALEIGH, N.C., May 28, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced the appointment of Dr. June S. Almenoff, M.D., Ph.D., FACP, as Chief Scientific Officer. Dr. Almenoff, an accomplished pharma executive with extensive gastroenterology and infectious diseases expertise, will lead the Company’s commercial strategy as it relates to medical and scientific matters, including the medical affairs activities for Talicia® (RHB-105)1 in preparation for potential U.S. commercial launch in the fourth quarter of 2019.
TEL-AVIV, Israel and RALEIGH, N.C., May 23, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that Mr. Adi Frish, Senior Vice President of Business Development and Licensing, will present a corporate overview at the 2019 BIO International Convention on Monday, June 3, 2019, at 1:30 p.m. EDT at the Pennsylvania Convention Center, Philadelphia, PA. A copy of the presentation to be delivered by Mr. Frish will be available on the Company's website and may be viewed at: http://ir.redhillbio.com. RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company, primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases.
TEL-AVIV, Israel and RALEIGH, N.C., May 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that it is expanding its commercial management team with several key executive hires ahead of the potential U.S. launch of Talicia®. The Company has appointed Rob Jackson as Vice President of Marketing, Robert J. Gilkin, Jr. as Vice President of Market Access and Steven Thomasian as Vice President of Supply Chain.